10-K: ABVC BioPharma Reports Fiscal Year 2024 Results, Navigates Financial Challenges

Sentiment:

Annual Results 15 April 2025 4:23 PM

ABVC BioPharma reports increased revenue for fiscal year 2024, but faces ongoing financial challenges and a restatement of prior year financials.

Delay expectedThe company targets to complete the title transfer by the end of 2025, subject to the timeline and outcome of regulatory reviews.

Capital raiseThe company may seek additional financing to provide the capital required to expand its production facilities, Research and development (R&D) initiatives and/or working capital, as well as to repay outstanding loans if cash flow from operations is insufficient to do so.

Worse than expectedThe company reported a net loss and a working capital deficit, indicating financial strain.A material weakness in internal control over financial reporting was identified, leading to a restatement of the 2023 financial statements.The company is facing challenges related to its NASDAQ listing, including maintaining the minimum bid price.

Summary

ABVC BioPharma, a clinical stage biopharmaceutical company, reported its fiscal year 2024 results.
The company's revenue increased to $509,589, primarily from out-licensing intellectual property and CDMO services.
Operating expenses decreased due to cost control initiatives.
The company experienced a net loss of $5,259,037 for the year.
A restatement of the 2023 financial statements was required due to errors in share-based payments, interest expense recognition, and non-controlling interest identification.
The company is working to address a material weakness in internal control over financial reporting.
ABVC is actively pursuing strategic partnerships and collaborations to advance its drug candidates.
The company is facing challenges related to its NASDAQ listing, including maintaining the minimum bid price.
ABVC is focusing on advancing its pipeline, including Vitargus and ABV-1504.
The company is working to transfer land ownership in Taiwan to YunZhiYi Co., Ltd.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue increased, the company is still operating at a loss and faces significant financial and operational challenges. The restatement and material weakness in internal controls are also concerning.

Positives

Revenue increased significantly due to out-licensing agreements.
Operating expenses decreased due to cost control measures.
Net loss decreased compared to the previous year.
The company is actively pursuing strategic partnerships and collaborations.
ABVC is making progress in advancing its drug and medical device pipeline.

Negatives

The company experienced a net loss of $5,259,037 for the year.
A material weakness in internal control over financial reporting was identified, leading to a restatement of the 2023 financial statements.
The company is facing challenges related to its NASDAQ listing, including maintaining the minimum bid price.
Working capital is in deficit of $4.4 million.

Risks

Unfavorable global economic conditions, including health and safety concerns, could adversely affect the business.
The company has no history in obtaining regulatory approval for, or commercializing, any new drug candidate.
Growth is dependent on the ability to successfully develop, acquire or license new drugs.
The company may be subject to product liability claims in the future.
The company faces substantial competition from companies with considerably more resources and experience.
The company is subject to the risks of doing business internationally, including periodic foreign economic downturns and political instability.
The share price of the company's common stock is volatile and may be influenced by numerous factors, some of which are beyond the company's control.
The company's failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a delisting of its Common Stock.

Future Outlook

The company plans to continue improving operations to generate positive cash flows and raise additional capital through private or public offerings, or financial support from related parties or shareholders.

Industry Context

The biotechnology industry is highly competitive and subject to significant and rapid technological change. ABVC competes with companies that research, develop, manufacture, and market already-existing and new pharmaceutical products in the fields of CNS, hematology/oncology, and autoimmune diseases.

Comparison to Industry Standards

The document does not provide enough information to compare ABVC's results to specific industry standards or comparable companies.
To perform a detailed comparison, we would need to analyze ABVC's financial metrics (e.g., revenue growth, R&D spending, profitability) against those of its peers in the biopharmaceutical industry.
Some potential comparable companies could include other small-cap biopharmaceutical firms focused on similar therapeutic areas and stages of development, such as: -Galectin Therapeutics Inc. (GALT): Focuses on developing therapies for fibrotic and inflammatory diseases.
-Oncolytics Biotech Inc. (ONCY): Develops oncolytic viruses for cancer treatment.
-Cyclacel Pharmaceuticals, Inc. (CYCC): Develops cancer therapies based on cell cycle biology.
When comparing ABVC to these companies, factors to consider would include: -Pipeline stage and clinical trial progress -Cash runway and funding sources -Market capitalization and investor sentiment -Partnerships and collaborations -Intellectual property portfolio
Without this comparative analysis, it's difficult to assess whether ABVC's performance is in line with or deviates from industry norms.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
CEO	Howard Doong	Uttam Patil	June 21, 2023	Howard Doong resigned.
CSO	Richard King	Tsung-Shann Jiang	June 15, 2023	Richard King resigned.
CFO	Leeds Chow	Uttam Patil (Interim)	March 5, 2025	Leeds Chow resigned.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Internal Control	The company identified material weaknesses in its internal control over financial reporting and is developing a plan to remediate them.	December 31, 2024	The material weaknesses resulted in a restatement of the 2023 financial statements and could adversely affect the company's ability to meet its reporting and financial obligations.

Related Party Transactions

The company has entered into various related party transactions, including collaborative agreements, loan agreements, and stock issuances with entities and individuals under common control or with significant influence over the company.
These transactions include agreements with BioFirst Corporation, Rgene Corporation, BioLite Japan K.K., and OncoX BioPharma, Inc.

Stakeholder Impact

Shareholders face the risk of dilution from future stock issuances and the potential for delisting from NASDAQ.
Employees may be affected by cost control measures and changes in management.
Customers and partners may be impacted by the company's ability to execute its business plan and advance its pipeline.
Creditors face the risk of default if the company is unable to generate positive operating cash flows and raise additional capital.

Next Steps

Continue to improve operations to generate positive cash flows.
Raise additional capital through private or public offerings, or financial support from related parties or shareholders.
Advance the pipeline, including Vitargus Phase II study and ABV-1505 Phase II Part II clinical study.
Pursue strategic collaborations, including agreements with ForSeeCon Eye Corporation and OncoX BioPharma, Inc.
Regain compliance with NASDAQ listing requirements, including maintaining a minimum bid price of $1.00 per share.
Complete the title transfer of land ownership in Taiwan to YunZhiYi Co., Ltd.

Key Dates

Date	Description
February 6, 2002	ABVC BioPharma, Inc. was incorporated in Nevada.
July 24, 2017	BriVision entered into a collaboration agreement with BioFirst.
May 26, 2017	American BriVision Corporation entered into a co-development agreement with Rgene Corporation.
August 19, 2022	Received a deficiency letter from Nasdaq regarding minimum bid price.
May 24, 2023	Received a deficiency letter from Nasdaq regarding minimum stockholders equity.
July 25, 2023	Filed a Certificate of Amendment to its Articles of Incorporation authorizing a 1-for-10 reverse stock split.
August 14, 2023	Entered into a cooperation agreement with Zhonghui United Technology (Chengdu) Group Co., Ltd.
November 12, 2023	The Company and BioLite, Inc. each entered into a multi-year, global licensing agreement with AiBtl BioPharma Inc.
January 17, 2024	Entered into a securities purchase agreement with Lind Global Fund II, LP.
February 6, 2024	Entered into a definitive agreement with Shuling Jiang for land transfer.
March 25, 2024	The Company, and one of its co-development partners, BioFirst Corporation, each entered into a twenty-year, global definitive licensing agreement with ForSeeCon Eye Corporation.
April 16, 2024	The Company entered into a definitive agreement with OncoX BioPharma, Inc.
May 8, 2024	The Company entered into a definitive agreement with OncoX BioPharma, Inc.
May 14, 2024	The Company entered into a definitive agreement with OncoX BioPharma, Inc.
May 16, 2024	The Companys board of directors determined that it was in the best interest of the Company and its shareholders to terminate the Agreement and not proceed with the transfer of land ownership.
May 23, 2024	The Company and its subsidiary, BioLite Inc (collectively, the licensor), each entered into a licensing agreement with OncoX.
July 10, 2024	Received a notification letter from the Staff notifying the Company that the minimum bid price per share for its common shares has been below $1.00 for a period of 30 consecutive business days.
January 9, 2025	Received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share.
March 5, 2025	Leeds Chow notified the Company of his resignation as CFO.
March 11, 2025	ABVC and BioLite each entered into an addendum to the licensing agreement with AiBtl.
March 31, 2025	Filed a Form 12b-25 stating that we required additional time to complete this annual report on Form 10-K.
April 1, 2025	Lind has converted $400,000 of 3rd Lind Note principal balance into 400,000 the Companys common stock, leaving outstanding principal of $600,000.
April 11, 2025	Date of share information.

Keywords

ABVC BioPharma, financial results, biopharmaceutical, clinical trials, licensing agreements, NASDAQ, revenue, net loss, internal control, drug development, medical devices

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.